NEW YORK (AP) -- Talecris Biotherapeutics Holdings Corp. said Friday the closing of its sale to Spanish health care company Grifols SA is being delayed by almost three months.
Grifols agreed to buy Talecris in June for $3.4 billion, or $26.16 per share in cash and stock. The companies had said they expected the deal to close by March 6, but now say the sale will close by June 30. The Federal Trade Commission has not cleared the deal, and Grifols is still working to get FTC approval.
Talecris is based in Research Triangle Park, N.C. It was the blood plasma unit of Bayer HealthCare before becoming a separate publicly traded company. Its shares rose 20 cents to $25.60 in morning trading.
Grifols agreed to buy Talecris in June for $3.4 billion, or $26.16 per share in cash and stock. The companies had said they expected the deal to close by March 6, but now say the sale will close by June 30. The Federal Trade Commission has not cleared the deal, and Grifols is still working to get FTC approval.
Talecris is based in Research Triangle Park, N.C. It was the blood plasma unit of Bayer HealthCare before becoming a separate publicly traded company. Its shares rose 20 cents to $25.60 in morning trading.